Estimating background rates of Guillain-Barré Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign-Reference-Cited by-同舟云学术

Estimating background rates of Guillain-Barré Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign

Published:2011-05-17 Issue:1 Volume:11 Page:
ISSN:1471-2458
Container-title:BMC Public Health
language:en
Short-container-title:BMC Public Health

Author:

Deeks Shelley L,Lim Gillian H,Simpson Mary Anne,Rosella Laura,Mackie Christopher O,Achonu Camille,Crowcroft Natasha S

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health

Link

http://link.springer.com/article/10.1186/1471-2458-11-329/fulltext.html

Reference25 articles.

1. Interim order respecting the sale of the vaccine for the novel influenza a H1N1 virus. [ http://www.hc-sc.gc.ca/dhp-mps/prodpharma/legislation/interimorders-arretesurgence/vaccin-eng.php ]

2. The Globe and Mail: Health officials scramble to counter H1N1 myths; Safety and effectiveness of vaccine emphasized in effort to reassure skeptics as conspiracy theories go viral. Reported by Caroline Alphonso. 2009

3. Ottawa Citizen: Nearly half of Canadians won't get H1N1 shot: poll; Health officials try to counter fear, confusion. Reported by Meagan Fitzpatrick. 2009

4. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, Eddins DL, Bryan JA: Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol. 1979, 110: 105-123.

5. Haber P, Sejvar J, Mikaeloff Y, DeStefano F: Vaccines and Guillain-Barré syndrome. Drug Saf. 2009, 32: 309-323. 10.2165/00002018-200932040-00005.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance;Vaccine;2022-05

2. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance;2022-01-16

3. Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study;BMJ Open;2021-12

4. Background rates of hospitalizations and emergency department visits for selected thromboembolic and coagulation disorders in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance;2021-04-04

5. Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017;Scientific Reports;2020-08-24